monoclonal antibody 3F8
monoclonal antibody 3F8 is a biological therapy with 9 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
9 of 9 finished
0.0%
0 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma
Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma
Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma
Clinical Trials (9)
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma
Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma
Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma
Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
All 9 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 9